Phase 1 Ovarian Cancer Trial, Recruiting NCT06515613 Sponsor: Context Therapeutics Inc. Condition: Ovarian Cancer
Back to Ovarian Cancer

Phase 1 Ovarian Cancer Trial, Recruiting

NCT06515613
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People diagnosed with ovarian, testicular, or endometrial cancer that tests positive for a protein called CLDN6, and whose cancer has stopped responding to platinum-based chemotherapy or has come back after treatment.
  • People whose cancer can be measured on scans according to a standard set of measurement rules called RECIST 1.1.
  • People who are reasonably active and able to carry out daily activities (rated on a standard scale as 0, 1, or 2), and whose doctors expect them to live for at least 12 weeks.
  • People whose liver, kidneys, heart, and other organs are functioning well enough to take part in the trial.

Who may not be able to join:

  • People whose cancer has spread to the brain, the lining of the brain or spinal cord, or is pressing on the spinal cord.
  • People with a serious active infection that is not under control, or any other medical condition that the trial doctor believes would make it unsafe to take part.
  • People who are already taking part in another clinical trial that is testing an investigational treatment.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Karen Chagin, MD, Context Therapeutics Inc.

Phone: 267-225-7416

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Context Therapeutics Inc.
Registry
ClinicalTrials.gov
Start date
10 July 2024
Est. completion
31 May 2028

Where this trial is recruiting

🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Incidence of Dose Limiting Toxicities (DLTs); Overall response rate (ORR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov